LFB has announced the first-in-man injections of its first two therapeutic monoclonal antibodies
During Q4 2008, two monoclonal antibodies developed by LFB's R&D division (an anti-D monoclonal and a batch of anti-CD 20) both achieved a significant development milestone - first-in-man administration.
The anti-D monoclonal (ADNC) is used in cases of rhesus incompatibility between a mother and her fetus. The Phase I safety and pharmacokinetic trial of ADNC is currently being performed in healthy volunteers. A Phase II efficacy trial will be performed at a center in Europe in the second half of 2009. In this indication, only polyclonal plasma immunoglobulins are currently available worldwide.
The anti-CD 20 targets a B lymphocyte surface antigen that is expressed in leukemia and lymphoma. The antibody is potentially indicated as a component in the therapy of rare cancers. The biomanufacturing company MAbgène (acquired by the LFB group in 2007 and located in Alès, southern France) has produced the batches needed to run the anti-CD20's initial clinical development program. The Phase I trial is currently investigating lymphoid leukemia patients at seven centers in France (led by the Institut Gustave Roussy cancer center near Paris).
In the field of plasma-derived drugs, LFB also filed (in late 2008) a biological license application for a new-generation, multivalent human immunoglobulin that is produced in a completely new process. In parallel with the development of this new drug, LFB has invested significantly at its facilities in Les Ulis (near Paris) and Lille (in northern France), in order to double its manufacturing capacity by 2011 and thus meet patients' growing therapeutic needs for immunoglobulins, in particular. A new manufacturing unit (with a capacity of 5.6 metric tons and to be fully dedicated to production of this novel immunoglobulin) is currently being qualified at the group's Lille site. LFB's new nanofiltered fibrinogen is also likely to gain marketing authorization later this year.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
